OakChart

EyePoint Inc

EYPTHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 2:27 PM ET

0.3727-0.0314 (-7.77%)
2026-11-11 20:27 CET
Market cap
34.84 USD m
Revenue, TTM
2.79 USD m
Net income, TTM
-306.64 USD m
Free cash flow, TTM
-271.28 USD m
EPS diluted, TTM
-3.74
P/E
-
Compare

Price

EYPT against its 20, 50 and 200-day averages
2050200missearnings
0.005.0010.0015.0092.2M184.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EYPTclose 0.3720-day 0.6550-day 2.50200-day 10.370.37

98.0% under the 52-week high of 19.11 on 8 Dec 2025. 52-week low 0.33 on 6 Nov 2026. Last 15 sessions, 32.6% high to low

Profile

EYPT
52-week range, 0% of the way up
0.3319.11

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

IndexRUT
Employees214
IPOJan 27, 2005
Beta1.88
ATR, 14d0.16
Rel volume0.54
Short float13.65%
Insider own6.38%
Inst own117.83%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap32.13M
Enterprise Value-125.97M
Income-306.64M
Sales2.79M
Book/sh1.96
Cash/sh2.09
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees214
IPOJan 27, 2005

Ratios

P/E-
Forward P/E-
PEG-
P/S11.52
P/B0.19
P/C0.18
P/FCF-
EV/EBITDA-
EV/Sales-45.15
Quick Ratio4.46
Current Ratio4.50
Debt/Eq0.13
LT Debt/Eq0.12
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.74
EPS next Y-2.14
EPS next Q-0.93
EPS this Y-14.57%
EPS next Y41.22%
EPS next 5Y27.67%
EPS past 3/5Y-4.94% 2.18%
Sales past 3/5Y-8.83% -1.85%
EPS Y/Y TTM-39.78%
Sales Y/Y TTM-94.63%
EPS Q/Q-28.45%
Sales Q/Q-90.49%
EarningsNov 12 BMO
EPS/Sales Surpr.-10.82% 14.45%

Ownership

Insider Own6.38%
Insider Trans0.10%
Inst Own117.83%
Inst Trans23.78%
ROA-115.86%
ROE-148.70%
ROIC-164.66%
Gross Margin-18.29%
Oper. Margin-11365.22%
Profit Margin-10994.73%
SMA20-43.09%
SMA50-85.10%
SMA200-96.41%
Trades-

Technical

Shs Outstand84.98M
Shs Float80.71M
Short Float13.65%
Short Ratio1.20
Short Interest11.02M
52W High19.11 -98.05%
52W Low0.33 12.77%
Volatility10.33% 11.36%
ATR (14)0.16
RSI (14)19.00
Beta1.88
Rel Volume0.54
Avg Volume9.21M
Volume3,866,131

Performance

Perf Week-5.65%
Perf Month-87.86%
Perf Quarter-97.24%
Perf Half Y-97.22%
Perf YTD-97.96%
Perf Year-96.80%
Perf 3Y-94.18%
Perf 5Y-97.30%
Perf 10Y-98.06%
Recom2.54
Target Price12.39
Prev Close0.40
Price0.37
Change %-7.77%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2026DowngradeMMizuhoOutperform → Neutral$0.50+34.2%
Oct 20, 2026DowngradeJJP MorganNeutral → Underweight
Oct 19, 2026DowngradeJJefferiesBuy → Hold$1+168.3%
Oct 19, 2026DowngradeGGuggenheimBuy → Neutral
Sep 02, 2026DowngradeTTD CowenBuy → Hold$4+973.2%
Aug 18, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$5+1,241.6%
Aug 18, 2026DowngradeHH.C. WainwrightBuy → Neutral
Aug 18, 2026DowngradeCChardan Capital MarketsBuy → Neutral$5+1,241.6%
Aug 17, 2026DowngradeCCantor FitzgeraldOverweight → Neutral
Jul 16, 2026InitiatedSStifelBuy$40+10,632.5%

Peers

Mkt cap
TickerCompanyMkt cap
OCULOcular Therapeutix Inc1.49B
KODKodiak Sciences Inc6.97B
SGPSpyGlass Pharma Inc1.15B
FDMT4D Molecular Therapeutics Inc699.94M
OTLKOutlook Therapeutics Inc117.07M
RGNXRegenxbio Inc585.76M
OCSOculis Holding AG474.11M
SRZNSurrozen Inc609.40M
BLTEBelite Bio Inc ADR6.33B
TARSTarsus Pharmaceuticals Inc3.79B

Insider trading

latest 14 of 33
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Zaderej Karen L.DirectorAug 18 '26Buy4.9310,60052,25849,100Aug 18 04:08 PM
Lurker NancyOfficerJul 21 '26Proposed Sale13.05421,2355,497,117Jul 21 04:44 PM
Duker Jay S.President and CEOJul 10 '26Option Exercise0.0016,667017,653Jul 14 04:07 PM
Ribeiro RamiroChief Medical OfficerJun 30 '26Option Exercise8.264,87540,2684,875Jul 02 04:03 PM
Ribeiro RamiroChief Medical OfficerJun 30 '26Sale15.014,87573,1670Jul 02 04:03 PM
Elston GeorgeChief Financial OfficerMay 25 '26Option Exercise0.007,500095,318May 27 04:05 PM
Ribeiro RamiroChief Medical OfficerApr 17 '26Option Exercise8.262,43720,1302,437Apr 20 04:07 PM
Ribeiro RamiroChief Medical OfficerApr 17 '26Sale15.002,43736,5550Apr 20 04:07 PM
Ramiro RibeiroOfficerApr 17 '26Proposed Sale14.819,750144,398Apr 17 04:36 PM
Duker Jay S.President and CEOMar 16 '26Buy13.151,50019,724100,665Mar 16 04:12 PM
Ribeiro RamiroChief Medical OfficerMar 04 '26Option Exercise8.262,43820,1382,438Mar 05 04:02 PM
Ribeiro RamiroChief Medical OfficerMar 04 '26Sale17.872,43843,5720Mar 05 04:02 PM
Ribeiro RamiroChief Medical OfficerFeb 17 '26Option Exercise8.262,43720,1302,437Feb 18 04:07 PM
Ribeiro RamiroChief Medical OfficerFeb 17 '26Sale15.002,43736,5550Feb 18 04:07 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VHTVanguard Health Care ETFAUM: 21.51B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.930--0.2313
2026Q22026-08-06-1.090-0.984-1.0900.510.4414
2026Q12026-05-06-0.990-0.805-0.9860.700.3512
2025Q42026-03-04-0.810-0.748-0.8140.620.9912
2025Q32025-11-05-0.850-0.769-0.8510.973.4912
2025Q22025-08-06-0.850-0.823-0.8505.336.6513
2025Q12025-05-07-0.650-0.673-0.64824.507.8913
2024Q42025-03-05-0.640-0.486-0.64111.6011.0813
2024Q32024-11-07-0.540-0.546-0.53910.5010.4112
2024Q22024-08-07-0.580-0.505-0.5799.5010.6311
2024Q12024-05-08-0.550-0.402-0.55311.709.9110
2023Q42024-03-07-0.330-0.486-0.33414.008.9011
2023Q32023-11-01-0.330-0.498-0.32915.207.868
2023Q22023-08-02-0.6101.384-0.6109.1079.105
2023Q12023-05-03-0.560-0.680-0.5657.707.607
2022Q42023-03-02-1.160-0.610-1.16310.5010.406

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.400-5.675-5.44520.3718.85
2020FY-3.540-1.820-3.53734.4445.60
2021FY-2.030-1.954-2.03136.9035.19
2022FY-2.740-2.185-2.74041.4041.28
2023FY-1.820-1.938-1.82046.0040.74
2024FY-2.320-2.173-2.32543.3042.55
2025FY-3.170-3.033-3.17031.3731.77
2026FY--3.632--1.67
2027FY--2.135--3.83
2028FY--1.200--120.16
2029FY-0.299--321.64
2030FY-1.060--433.01

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-3113010.300.001.00
2026Q4S2026-10-2813110.300.001.00
2026Q4S2026-10-2413310.300.001.00
2026Q4S2026-10-2013320.300.001.00
2026Q4S2026-09-1113440.300.001.00
2026Q4S2026-08-1713440.300.001.00
2026Q4S2026-08-1413340.290.001.00
2026Q4S2026-08-1014250.300.001.00
2026Q4S2026-08-0914240.340.001.00
2026Q4S2026-08-0614340.340.001.00
2026Q4S2026-08-0514120.320.000.81
2026Q4S2026-08-0314110.340.000.81
2026Q4S2026-07-2814100.340.000.81
2026Q4S2026-07-2014100.340.000.81

Estimate history

EPS, annual-5.2-10.5-5.445-3.537-2.031-2.74-1.82-2.325-3.167-3.7436
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.579-0.539-0.641-0.648-0.85-0.851-0.814-0.986-1.092
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual7.5395.85620.36534.43736.93941.40446.01843.27331.3712.79
Period201720182019202020212022202320242025TTM
Sales, quarterly9.47710.52411.58824.4535.3330.9660.620.6960.507
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.9369.53710.94218.1433.90634.08349.04368.26682.82684.982
Period201720182019202020212022202320242025MRQ
Shares, quarterly52.1653.52468.26668.81168.8969.5782.82683.45384.982
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.7931.3743.2746.0241.4036.9434.4420.365.86
Cost of Goods Sold Incl. D&A3.304.383.714.6310.3810.648.285.15-
Gross Profit-0.5127.0039.5641.3931.0326.3026.1515.22-
Selling, General and Administrative Excl. Other316.47270.43185.41115.05109.9781.5863.4463.0852.32
Research and Development262.73221.04132.9364.3649.6428.5017.4215.3720.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-316.98-243.43-145.85-73.66-78.94-55.28-37.29-47.86-49.12
Interest Expense-0.030.011.253.195.507.266.183.28
Unusual Expense0.000.000.002.7522.26-2.060.913.8118.89
Net Income Before Taxes-306.51-231.68-130.78-70.71-102.25-58.42-45.39-56.79-89.44
Income Taxes0.140.280.090.080.000.000.000.000.00
Consolidated Net Income-306.64-231.96-130.87-70.80-102.25-58.42-45.39-56.79-89.44
Net Income From Continuing Operations-306.64-231.96-130.87-70.80-102.25-58.42-45.39-56.79-89.44
Net Income-306.64-231.96-130.87-70.80-102.25-58.42-45.39-56.79-89.44
EPS (Recurring)-3.54-3.17-2.32-1.77-2.32-2.08-3.49-5.19-8.96
EPS (Basic, Before Extraordinaries)-3.74-3.17-2.32-1.82-2.74-2.03-3.54-5.44-10.50
EPS (Diluted)-3.74-3.17-2.32-1.82-2.74-2.03-3.54-5.44-10.50
EBITDA-314.38-241.12-144.31-73.20-76.49-52.51-34.64-45.26-46.47
Non-Operating Income (Expense)10.4711.7815.096.952.130.290.061.05-18.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00-
Stock Option Compensation Expense29.1722.0229.029.5314.187.455.554.574.03
Price To Sales Ratio443.7342.669.6919.543.159.532.457.9427.45
Gross Margin-18.2986.0591.4289.9374.9471.2075.9474.73-
Operating Margin-11,365.22-775.98-337.06-160.07-190.65-149.64-108.28-235.02-838.76
Net Margin-10,994.73-739.42-302.43-153.84-246.97-158.14-131.82-278.88-1,527.32
Shares Outstanding84.9882.8368.2749.0434.0833.9118.1410.949.54
Market Capitalization34.8434.84508.47816.00119.29414.8694.43169.60180.25

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.510.700.620.975.3324.4511.5910.52
Cost of Goods Sold Incl. D&A0.691.160.720.720.700.810.820.74
Gross Profit-0.18-0.47-0.100.244.6323.6510.779.79
Selling, General and Administrative Excl. Other97.2086.7670.2462.2766.8672.4856.0142.54
Research and Development83.6172.1559.2147.7555.5058.5743.3729.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-97.38-87.23-70.34-62.02-62.23-48.84-45.24-32.75
Interest Expense0.000.00--0.00-0.010.00
Unusual Expense0.000.000.000.00-0.000.000.00
Net Income Before Taxes-94.47-84.88-67.42-59.73-59.33-45.20-41.31-29.36
Income Taxes0.00-0.050.190.000.090.000.090.00
Consolidated Net Income-94.47-84.83-67.61-59.73-59.43-45.20-41.40-29.36
Net Income From Continuing Operations-94.47-84.83-67.61-59.73-59.43-45.20-41.40-29.36
Net Income-94.47-84.83-67.61-59.73-59.43-45.20-41.40-29.36
EPS (Recurring)-1.09-0.99-0.81-0.85-0.85-0.65-0.64-0.54
EPS (Basic, Before Extraordinaries)-1.09-0.99-0.81-0.85-0.85-0.65-0.64-0.54
EPS (Diluted)-1.09-0.99-0.81-0.85-0.85-0.65-0.64-0.54
EBITDA-96.69-86.59-69.65-61.45-61.69-48.34-44.77-32.34
Non-Operating Income (Expense)2.912.342.922.292.893.643.943.39
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.219.195.336.435.437.826.247.45
Price To Sales Ratio443.73145.5748.3523.6012.686.7511.119.52
Gross Margin-36.09-67.24-16.7725.3686.8296.7192.9693.01
Operating Margin-19,207.10-12,532.47-11,345.97-6,420.81-1,166.83-199.72-390.40-311.17
Net Margin-18,633.14-12,188.51-10,904.68-6,183.44-1,114.31-184.82-357.26-278.99
Shares Outstanding84.9883.4582.8369.5768.8968.8168.2753.52
Market Capitalization34.841,075.441,512.52981.53647.52372.51508.47427.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2018FY
Cash & Short Term Investments306.09370.91331.05144.56211.5644.9122.2145.2638.78
Short Term Receivables0.650.610.8115.5018.359.4511.370.630.35
Inventories1.812.313.912.893.625.342.140.28-
Other Current Assets20.119.489.049.864.223.426.001.430.78
Total Current Assets328.65383.31344.80172.81237.7563.1241.7247.6039.91
Net Property, Plant & Equipment29.2529.1810.237.402.733.243.440.290.25
Total Investments and Advances0.150.150.150.150.150.150.150.150.15
Intangible Assets--0.000.0022.7525.2127.6730.1331.36
Other Assets5.955.830.000.000.000.000.000.000.00
Total Assets364.00418.46355.18180.36263.3791.7272.9778.1771.67
Short Term Debt Incl. Current Port. of LT Debt2.021.250.5611.050.780.690.48-0.00
Accounts Payable10.4911.726.505.927.384.814.192.642.94
Other Current Liabilities24.5136.0856.2017.5615.499.396.8518.8218.72
Total Current Liabilities37.0249.0563.2634.5423.6614.8911.5221.4621.66
Long Term Debt20.7721.864.9135.2938.4640.3850.1217.6217.31
Provision for Risks Charges0.000.000.000.000.000.000.00-0.00
Other Liabilities0.0911.0620.6914.1616.8817.913.001.4621.01
Total Liabilities57.8881.9688.8683.9978.9973.1864.6440.5359.98
Non-Equity Reserves0.000.000.000.000.000.000.00-0.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity306.11336.50266.3296.37184.3818.548.3337.6311.69
Total Shareholders Equity306.11336.50266.3296.37184.3818.548.3337.6311.69
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity306.11336.50266.3296.37184.3818.548.3337.6311.69
Total Liabilities & Stockholders Equity364.00418.46355.18180.36263.3791.7272.9778.1771.67
Book Value Per Share3.704.935.432.835.441.020.763.950.16
Tangible Book Value Per Share3.704.935.432.834.77-0.37-1.770.79-0.26
Full-Time Employees214165121144123101845544
Price to Book Ratio0.211.8213.920.872.256.4420.364.7913.68
Return on Assets-59.29-33.83-26.44-46.09-32.90-55.13-75.15-184.71-117.70
Return on Equity-72.19-43.42-39.04-72.84-57.58-337.87-247.12-350.96-424.98
Return on Invested Capital-70.96-36.52-26.10-77.66-26.22-77.04-97.16-161.87-183.37
Quick Ratio8.837.775.394.929.903.883.442.21-
Current Ratio8.887.815.455.0010.054.243.622.221.84

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-306.64-231.96-130.87-70.80-102.25-58.42-45.39-56.79-44.72
Depreciation2.602.311.540.462.452.772.652.601.33
Other Funds (Non Cash)31.0523.0530.7913.2437.837.298.1710.0321.75
Funds from Operations-272.62-206.33-98.45-57.01-61.98-48.36-34.57-44.16-21.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital5.33-33.78-27.7758.88-3.02-1.7420.14-12.54-0.94
Cash from Operating Activities-267.30-240.11-126.231.88-65.00-50.10-14.44-56.70-22.59
Capital Expenditures-3.98-3.28-4.05-3.48-2.15-0.16-0.36-0.21-0.13
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.150.150.000.000.000.000.000.00-
Purchase or Sale of Investments118.7071.70-215.300.17-15.12-32.970.000.00-
Purchase of Investments-168.60-252.02-398.30-55.12-139.12-32.970.000.00-
Sale Or Maturity of Investments287.30323.73183.0055.28124.000.000.000.00-
Other Uses0.000.000.000.000.000.000.000.00-
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities114.8868.58-219.35-3.31-17.27-33.12-0.36-0.21-0.13
Cash Dividends Paid0.000.000.000.000.000.000.000.00-
Change in Capital Stock195.58175.14169.31229.550.40217.2050.2123.0429.40
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-
Sale of Common Pref Stock195.58175.14169.31229.550.40217.2050.2123.0429.40
Proceedsfrom Stock Options192.52172.90163.31226.170.00216.8249.9222.630.00
Issuance or Reduction of Debt, Net-0.11-0.10-0.10-40.512.10-0.15-11.8028.66-
Change in Long Term Debt-0.11-0.10-0.10-40.512.10-0.15-11.8028.66-
Issuance of Long Term Debt0.000.000.005.3073.880.002.0448.66-
Reduction of Long Term Debt-0.11-0.10-0.10-45.81-71.77-0.15-13.84-20.00-
Net Financing Active Other Cash Flow-3.73-1.39-5.18-1.97-3.19-0.15-0.92-17.84-0.20
Other Financing Activities Uses-3.73-1.39-5.18-1.97-3.19-0.15-0.92-17.84-0.20
Cash from Financing Activities191.74173.65164.02187.07-0.69216.9037.4933.8629.20
Exchange Rate Effect-----0.000.000.00-0.00
Net Change in Cash39.312.12-181.56185.63-82.96133.6822.70-23.056.49
Free Cash Flow-271.28-243.39-130.28-1.61-67.16-50.25-14.80-56.91-22.72
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.280.090.080.000.000.000.00-

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments180.47222.54306.09204.02255.73318.19
Short Term Receivables0.091.160.651.040.620.44
Inventories1.881.251.812.112.682.13
Other Current Assets6.3824.5520.118.936.216.22
Total Current Assets188.82249.50328.65216.11265.25326.98
Net Property, Plant & Equipment29.8629.2629.2529.5229.8529.55
Total Investments and Advances0.150.150.150.150.150.15
Other Assets9.379.305.955.925.895.88
Total Assets228.19288.22364.00251.69301.15362.56
Short Term Debt Incl. Current Port. of LT Debt2.552.082.021.960.001.77
Accounts Payable17.2718.8110.4910.0819.6816.42
Other Current Liabilities22.1216.5624.5118.0613.4923.49
Total Current Liabilities41.9437.4637.0230.0933.1741.68
Long Term Debt19.8120.2320.7721.3021.8222.31
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.020.060.090.120.150.18
Total Liabilities61.7857.7457.8851.5155.1464.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity166.41230.47306.11200.18246.01298.40
Total Shareholders Equity166.41230.47306.11200.18246.01298.40
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity166.41230.47306.11200.18246.01298.40
Total Liabilities & Stockholders Equity228.19288.22364.00251.69301.15362.56
Book Value Per Share1.962.763.702.883.574.34
Tangible Book Value Per Share1.962.763.702.883.574.34
Full-Time Employees--214---
Price to Book Ratio0.213.496.353.992.171.10
Return on Assets-115.86-83.47-59.29-74.47-56.09-42.43
Return on Equity-148.70-102.71-72.19-98.23-73.95-53.54
Return on Invested Capital-50.73-33.84-20.68-26.97-22.19-14.09
Quick Ratio4.466.638.837.117.917.79
Current Ratio4.506.668.887.188.007.85

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-94.47-84.83-67.61-59.73-59.43-45.20
Depreciation0.690.640.700.580.540.50
Other Funds (Non Cash)8.9110.865.815.485.676.09
Funds from Operations-84.87-73.34-60.74-53.68-53.30-38.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital22.53-7.21-4.31-5.67-9.29-14.51
Cash from Operating Activities-62.35-80.55-65.05-59.35-62.59-53.12
Capital Expenditures-1.20-1.00-0.99-0.80-1.22-0.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.150.000.000.00
Purchase or Sale of Investments76.3060.05-73.8356.1849.5639.80
Purchase of Investments0.00-9.95-148.84-9.82-53.94-39.42
Sale Or Maturity of Investments76.3070.0075.0066.00103.5079.22
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities75.1059.05-74.6755.3848.3439.52
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock20.181.13166.717.560.270.59
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock20.181.13166.717.560.270.59
Proceedsfrom Stock Options19.620.00166.246.660.000.00
Issuance or Reduction of Debt, Net-0.03-0.03-0.03-0.03-0.02-0.04
Change in Long Term Debt-0.03-0.03-0.03-0.03-0.02-0.04
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.03-0.03-0.03-0.03-0.02-0.04
Net Financing Active Other Cash Flow-0.16-3.710.27-0.13-0.02-1.51
Other Financing Activities Uses-0.16-3.710.27-0.13-0.02-1.51
Cash from Financing Activities19.99-2.61166.967.400.24-0.95
Net Change in Cash32.75-24.1127.243.43-14.02-14.55
Free Cash Flow-63.55-81.55-66.03-60.15-63.81-53.40

Revenue breakdown

License And Collaboration Agreement2024: 38.50M 2025: 16.73M
Product2024: 3.16M 2025: 1.60M
Royalty2024: 1.61M 2025: 13.04M
China2024: 1.12M 2025: 1.29M
United Kingdom2024: 100.00K 2025: 100.00K
United States2024: 42.05M 2025: 29.98M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.65%11.0M80.7M8.93M
2026-10-1526.34%21.3M80.7M4.01M
2026-09-3025.76%20.8M80.7M3.86M
2026-09-1524.54%19.8M80.7M3.49M
2026-08-3122.44%18.1M80.7M3.14M
2026-08-1422.87%18.4M80.6M1.46M
2026-07-3122.42%18.0M80.3M1.28M
2026-07-1521.02%16.4M78.1M1.17M
2026-06-3019.34%15.1M78.1M1.06M
2026-06-1519.30%15.1M78.1M947.23K
2026-05-2919.32%15.1M78.1M1.04M
2026-05-1518.11%14.2M78.1M1.26M
2026-04-3019.26%14.2M73.6M1.32M
2026-04-1518.64%13.7M73.3M1.34M
2026-03-3118.28%13.4M73.2M1.36M
2026-03-1317.05%12.5M73.2M1.42M
2026-02-2714.85%10.9M73.2M1.31M
2026-02-1313.12%9.5M72.6M1.12M
2026-01-3011.82%8.6M73.1M1.17M
2026-01-1511.32%8.3M73.1M1.23M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.053.8467,40374.000.421-0.0050.000
call1.000.000.050.026.5107400.000.321-0.0080.000
call1.500.002.150.007.7960.000.000.295-0.0090.000
call2.000.000.050.007.8260.000.000.270-0.0090.000
call2.500.000.050.059.2031,0500.000.273-0.0100.000
call3.000.000.051.558.8661.000.000.255-0.0100.000
call3.500.002.900.0210.0906.000.000.262-0.0110.000
call4.000.000.050.0310.4203,0703400.259-0.0110.000
call4.500.000.850.0010.7040.000.000.256-0.0110.000
call5.000.000.050.0310.9565,9692050.253-0.0110.000
call5.500.000.050.0010.2880.000.000.239-0.0110.000
call6.000.000.050.0310.48145.000.000.237-0.0110.000
call7.500.000.050.0411.87214,5200.000.245-0.0120.000
call10.000.000.050.0212.5026,7110.000.240-0.0130.000
put0.500.100.200.224.7422,6921.00-0.579-0.0050.000
put1.000.551.000.640.0009.000.00-0.679-0.0070.000
put1.501.053.701.150.0000.000.00-0.705-0.0090.000
put2.001.601.701.209.6800.000.00-0.719-0.0090.000
put2.502.052.202.1510.3225,0904.00-0.727-0.0100.000
put3.002.552.702.7010.8292.000.00-0.733-0.0100.000
put3.503.005.303.200.0001.000.00-0.738-0.0100.000
put4.003.503.703.7011.6115,0010.00-0.741-0.0100.000
put4.504.006.304.150.0002.000.00-0.744-0.0110.000
put5.004.504.704.7012.2045,0060.00-0.747-0.0110.000
put5.505.005.205.1612.4491.000.00-0.749-0.0110.000
put6.005.505.705.7012.6722.002.00-0.751-0.0110.000
put7.507.007.207.1013.2631.000.00-0.755-0.0110.000
put10.009.509.709.6014.0162.000.00-0.760-0.0110.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13G/ASEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13GSEC
2026-10-198-KCurrent report2026-10-17SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-10-07SCHEDULE 13G/ASEC
2026-09-108-KCurrent report2026-09-10SEC
2026-09-08SCHEDULE 13GSEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-178-KCurrent report2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13GSEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13GSEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-22144/ASEC
2026-07-22144/ASEC
2026-07-21144Filing for proposed sale of securities under Rule 144.SEC
2026-07-178-KCurrent report2026-07-13SEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-03SCHEDULE 13GSEC
2026-05-274Statement of changes in beneficial ownership of securities2026-05-25SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-148-KCurrent report2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0852.26K100
2026-070000
2026-060073.17K1
2026-050000
2026-040036.56K1
2026-0319.72K143.57K1
2026-020036.56K1
2026-0100727.32K1
2025-12001.08M2
2025-110042.07K3

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC9.90%
BlackRock, Inc.8.90%
FEDERATED HERMES, INC.6.78%
ADAGE CAPITAL PARTNERS GP, L.L.C.5.76%
FRANKLIN RESOURCES INC5.73%
Commodore Capital LP5.49%
Jupiter Topco LLC4.50%
VANGUARD CAPITAL MANAGEMENT LLC4.33%
Aberdeen Group plc3.54%
Paradigm Biocapital Advisors LP3.45%

Funds

Fund% owned
Federated Hermes Kaufmann Fund3.31%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.15%
iShares Russell 2000 ETF2.41%
Federated Hermes Kaufmann Small Cap Fund2.36%
Eventide Healthcare & Life Sciences Fund1.49%
abrdn Healthcare Investors1.46%
Franklin Biotechnology Discovery Fund1.34%
Franklin Small Cap Growth Fund1.29%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Fidelity Small Cap Index Fund1.01%

OakChart. EYPT. Cached 15 minutes.